imatinib
protein
tyrosin
kinas
inhibitor
act
bcrabl
gene
abnorm
philadelphia
chromosom
chronic
myeloid
leukemia
cml
also
use
philadelphiaposit
acut
lymphocyt
leukemia
gastrointestin
stromal
tumor
gist
inhibit
ctransmembran
receptor
ckit
platelet
deriv
growth
factor
pdgf
tyrosin
howev
imatinib
variou
side
effect
commonli
caus
pleural
effus
gener
edema
addit
nausea
muscl
cramp
abdomin
pain
skin
rash
diarrhea
occur
incid
sever
respiratori
advers
event
rare
particular
interstiti
pneumon
extrem
uncommon
incid
korea
knowledg
three
case
imatinibinduc
pneumon
report
develop
two
patient
cml
one
moreov
report
success
rechalleng
imatinib
herein
describ
case
imatinibinduc
interstiti
pneumon
patient
cml
improv
temporarili
stop
drug
start
steroid
therapi
pateint
restart
imatinib
control
underli
diseas
without
recurr
pneumon
month
followup
man
admit
hospit
week
dyspnea
diagnos
cml
month
ago
took
mg
imatinibday
month
vital
sign
blood
pressur
mm
hg
puls
rate
respiratori
rate
bodi
temperatur
present
acut
illlook
appear
specif
find
note
neck
abdomin
examin
heart
beat
regular
breath
sound
clear
laboratori
find
follow
white
blood
cell
segment
neutrophil
lymphocyt
eosinophil
hemoglobin
gdl
platelet
creactiv
protein
mgdl
normal
rang
mgdl
total
protein
gdl
albumin
gdl
aspart
aminotransferasealanin
aminotransferas
ul
lactat
dehydrogenas
iul
blood
urea
nitrogencreatinin
mgdl
arteri
blood
ga
analysi
room
air
reveal
ph
mm
hg
mm
hg
meql
oxygen
satur
chest
xray
show
diffus
ground
glass
opac
reticular
nodul
lung
field
figur
chest
comput
tomographi
ct
scan
reveal
patchi
ground
glass
opac
septal
thicken
middl
lower
zone
lung
figur
pulmonari
function
test
show
forc
vital
capac
fvc
l
predict
valu
forc
expiratori
volum
second
l
predict
valu
carbon
monoxid
diffus
capac
underw
bronchoscopi
bronchoalveolar
lavag
bal
transbronchi
lung
biopsi
tblb
differenti
count
bal
fluid
reveal
macrophag
lymphocyt
neutrophil
eosinophil
microbiolog
studi
includ
cultur
bacteria
fungu
pneumocysti
jirovecii
mycobacterium
bronchial
specimen
neg
polymeras
chain
reaction
assay
mycoplasma
pneumonia
nine
respiratori
virus
influenza
viru
b
respiratori
syncyti
viru
metapneumo
viru
rhino
viru
parainfluenza
viru
adeno
viru
corona
viru
bocaviru
cytomegaloviru
neg
histolog
find
tblb
lingular
segment
demonstr
fibroblast
plug
format
alveoli
infiltr
chronic
inflammatori
cell
type
ii
pneumocyt
prolifer
mild
fibrou
thicken
interstitium
suggest
organ
pattern
interstiti
pneumonia
figur
evid
suggest
infecti
pneumonia
thu
strongli
suspect
druginduc
interstiti
pneumon
caus
imatinib
stop
imatinib
start
mgkg
prednisolon
daili
week
treatment
dyspnea
abnorm
xray
find
improv
discharg
mg
prednisolon
figur
month
treatment
restart
mg
imatinib
control
underli
diseas
concomit
mg
prednisolon
recurr
respiratori
symptom
observ
chest
ct
week
imatinib
rechalleng
figur
recent
mani
target
antineoplast
agent
gefitinb
erlotinib
imatinib
bevacitumab
rituximab
commonli
use
treat
variou
malign
although
incid
pulmonari
toxic
rare
target
therapi
drug
induc
sever
respiratori
event
interstiti
pneumon
pulmonari
imatinib
caus
pulmonari
complic
pleural
effus
pneumon
largest
studi
imatinib
treatment
ohnishi
et
report
among
patient
treat
drug
case
interstiti
lung
diseas
advers
event
median
period
develop
interstiti
pneumon
start
drug
day
median
daili
dose
drug
time
diagnosi
mg
howev
signific
correl
observ
develop
diseas
dose
durat
imatinib
incid
diseas
seem
higher
patient
preexist
pulmonari
diseas
current
case
took
day
interstiti
pneumon
occur
dosag
imatinib
mgday
current
patient
previou
lung
diseas
although
pathophysiolog
imatinibinduc
interstiti
pneumon
identifi
clearli
noncytotox
cytotox
type
suggest
possibl
noncytotox
type
manifest
eosinophil
pneumonia
hypersensit
pneumon
obstruct
bronchiol
wherea
cytotox
pattern
manifest
interstiti
edema
lymphocyt
infiltr
destruct
alveolar
epitheli
cell
addit
imatinib
aggrav
interstiti
pneumon
inhibit
pdgf
tyrosin
kinas
lead
acut
lung
diagnosi
made
base
histori
clinic
symptom
radiolog
find
patholog
result
chest
radiograph
show
divers
pattern
hypersensit
reaction
interstiti
pneumon
cryptogenicorgan
pneumonia
nodular
peribronchovascular
lesion
diffus
alveolar
patholog
manifest
also
vari
includ
diffus
alveolar
damag
nonspecif
interstiti
pneumonia
bronchiol
obliteran
organ
pneumonia
eosinophil
pneumonia
pulmonari
current
case
strongli
suggest
initi
lung
histolog
show
fibrou
plug
alveoli
infiltr
inflammatori
cell
interstitium
exclus
infecti
caus
via
microbiolog
clinic
studi
final
confirm
druginduc
interstiti
pneumon
due
improv
pneumon
discontinu
caus
drug
initi
steroid
therapi
standard
treatment
stop
drug
observ
cours
diseas
option
administ
although
prognos
divers
mostli
diseas
mild
resolv
promptli
rare
caus
fatal
irrevers
result
respiratori
failur
perman
structur
distort
addit
prognosi
might
poor
patient
histori
lung
diseas
option
manag
underli
diseas
patient
imatinibinduc
pneumon
report
ohnishi
et
found
patient
imatinibinduc
interstiti
pneumon
recov
corticosteroid
treatment
discontinu
drug
report
four
patient
readminist
mg
imatinib
daili
relaps
interstiti
pneumon
deloma
et
report
case
patient
cml
pneumon
relaps
switch
nilotinb
three
case
imatinibinduc
interstiti
pneumonia
report
korea
two
cml
one
patient
patient
cml
stop
imatinib
treatment
took
steroid
therapi
die
patient
cml
recov
steroid
therapi
chang
imatinib
nilotinib
surviv
patient
gist
improv
discontinu
imatinib
commenc
steroid
therapi
present
case
first
domest
report
success
imatinib
rechalleng
patient
cml
recoveri
interstiti
pneumon
without
recurr
month
followup
howev
symptom
chest
radiograph
monitor
pneumon
relaps
occur
readministr
drug
addit
studi
durat
discontinu
imatinib
start
steroid
therapi
optim
time
imatinib
rechalleng
superior
imatinib
retrial
switch
anoth
drug
requir
conclus
imatinibinduc
pneumon
fatal
irrevers
result
confus
common
infecti
diseas
import
clinician
consid
possibl
imatinibinduc
pneumon
patient
develop
respiratori
symptom
abnorm
radiolog
featur
imatinib
treatment
addit
kept
mind
sussecc
rechalleng
imatinib
coud
anoth
option
underli
diseas
recoveri
interstiti
pneumon
relat
imatinib
mesyl
